Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
COR · NYSE · Healthcare
Fundamental quality
53
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its financial strength drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $213,989M | $1,540M | $2,228M | $3,837M |
| 2022 | $238,587M | $1,699M | $2,207M | $2,315M |
| 2023 | $262,173M | $1,745M | $3,453M | $2,195M |
| 2024 | $293,959M | $1,509M | $2,998M | $1,255M |
| 2025 | $321,333M | $1,554M | $3,207M | $3,305M |
Between 2021 and 2025, revenue went from $213,989M to $321,333M (+50%) and net income went from $1,540M to $1,554M (+1%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Cencora, Inc. a profitable company?
Cencora, Inc. is profitable, with a net margin of 0.8%, though a thin one.
Does Cencora, Inc. have a lot of debt?
A moderate level: its net debt is 2.68 times its EBITDA.
Is Cencora, Inc. growing?
Its revenue has grown 9.6% annualized in recent years and its earnings per share 14.8%.
Does Cencora, Inc. generate cash?
Yes. It converts about 0.5% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Cencora, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →